Who are LY03005 extended-release tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): sodium valproate with Clozapine, Crushed ticagrelor, morphine,metoclopramide, risperidone (Risperdal), Risperidone and Ramelteon, Abilify (aripiprazole), aripiprazole long acting injectable formulation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ly03005-extended-release-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

LY03005 extended-release tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LY03005 extended-release tablet (LY03005 extended-release tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine D2 receptor antagonist (antipsychotic). Area: Psychiatry/Neurology.

phase 3 Dopamine D2 receptor antagonist (antipsychotic) Dopamine D2 receptor Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

LY03005 extended-release tablet (LY03005 extended-release tablet) — Luye Pharma Group Ltd.. LY03005 is a dopamine D2 receptor antagonist that blocks dopamine signaling in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LY03005 extended-release tablet TARGET	LY03005 extended-release tablet	Luye Pharma Group Ltd.	phase 3	Dopamine D2 receptor antagonist (antipsychotic)	Dopamine D2 receptor
sodium valproate with Clozapine	sodium valproate with Clozapine	Shanghai Mental Health Center	marketed	Antipsychotic + mood stabilizer combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase
Crushed ticagrelor, morphine,metoclopramide	Crushed ticagrelor, morphine,metoclopramide	Collegium Medicum w Bydgoszczy	marketed	Antiplatelet agent + opioid analgesic + antiemetic (combination therapy)	P2Y12 receptor (ticagrelor); mu opioid receptors (morphine); dopamine D2 receptors (metoclopramide)
risperidone (Risperdal)	risperidone (Risperdal)	University of South Florida	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Risperidone and Ramelteon	Risperidone and Ramelteon	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic + melatonin receptor agonist combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors
Abilify (aripiprazole)	Abilify (aripiprazole)	Genovate Biotechnology Co., Ltd.,	marketed	Atypical antipsychotic	Dopamine D2 receptor (partial agonist), Serotonin 5-HT1A receptor (partial agonist)
aripiprazole long acting injectable formulation	aripiprazole long acting injectable formulation	Vanguard Research Group	marketed	Atypical antipsychotic (dopamine partial agonist)	Dopamine D2 receptor, Dopamine D3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine D2 receptor antagonist (antipsychotic) class)

Luye Pharma Group Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LY03005 extended-release tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/ly03005-extended-release-tablet. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing